PMID- 23141142 OWN - NLM STAT- MEDLINE DCOM- 20130619 LR - 20161125 IS - 1096-0023 (Electronic) IS - 1043-4666 (Linking) VI - 61 IP - 1 DP - 2013 Jan TI - Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPARalpha) in human hepatocarcinoma HepG2 cells by activation of NF-kappaB pathway. PG - 266-74 LID - S1043-4666(12)00740-5 [pii] LID - 10.1016/j.cyto.2012.10.007 [doi] AB - Peroxisome proliferator activated receptor-alpha (PPARalpha) plays a major role in the regulation of lipid and glucose homeostasis, and inflammatory responses. The objectives of the study were to systematically investigate the effects of TNF-alpha and its regulatory pathway on PPARalpha expression in HepG2 cells using Real-Time RT-PCR and western blot analysis. Here, TNF-alpha suppressed PPARalpha mRNA expression in a dose- and time-dependent manner at the level of gene transcription. Pre-treatment of cells with 10muM of Wedelolactone for 2h was sufficient to restore PPARalpha expression to basal levels and also affected the expression of PPARalpha-regulated genes. This study also demonstrated that TNF-alpha represses PPARalpha expression by augmenting the activity of canonical NF-kappaB signalling pathway. This was shown by the abrogation of TNF-alpha-mediated PPARalpha down-regulation, after both p65 and p50 were knocked down via siRNA. The IKK contributes to IkappaBalpha degradation and mediates inducible phosphorylation of p105 at Ser933. Surprisingly, phosphorylation of p65 at Ser468 and Ser536 were severely abrogated with Wedelolactone inhibition, suggesting that Ser468 and Ser536, but not Ser276, may mediate the TNF-alpha inhibitory action on PPARalpha gene expression. These results suggest that TNF-alpha might, at least in part, suppress PPARalpha expression through activation of IKK/p50/p105/p65 pathway. Furthermore, phosphorylation of p65 at Ser468 and Ser536 may play a crucial role in the mechanism that limits PPARalpha production in the human HepG2 cells. CI - Copyright (c) 2012 Elsevier Ltd. All rights reserved. FAU - Lim, Wyi Sian AU - Lim WS AD - Department of Biomedical Science, Faculty of Science, Universiti Tunku Abdul Rahman, Bandar Barat, 31900 Kampar, Perak, Malaysia. FAU - Ng, Di Lin AU - Ng DL FAU - Kor, Sue Bee AU - Kor SB FAU - Wong, Hong Kin AU - Wong HK FAU - Tengku-Muhammad, Tengku Sifzizul AU - Tengku-Muhammad TS FAU - Choo, Quok Cheong AU - Choo QC FAU - Chew, Choy Hoong AU - Chew CH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121108 PL - England TA - Cytokine JT - Cytokine JID - 9005353 RN - 0 (Coumarins) RN - 0 (NF-kappa B) RN - 0 (NF-kappa B p50 Subunit) RN - 0 (NFKB1 protein, human) RN - 0 (PPAR alpha) RN - 0 (RNA, Messenger) RN - 0 (RNA, Small Interfering) RN - 0 (Transcription Factor RelA) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0K6L725GNS (wedelolactone) RN - EC 2.7.11.10 (I-kappa B Kinase) SB - IM EIN - Cytokine. 2013 Feb;61(2):691 MH - Carcinoma, Hepatocellular/*metabolism MH - Cell Line, Tumor MH - Coumarins/pharmacology MH - Down-Regulation MH - Hep G2 Cells MH - Humans MH - I-kappa B Kinase/genetics/metabolism MH - Liver Neoplasms/metabolism MH - NF-kappa B/*metabolism MH - NF-kappa B p50 Subunit/genetics/metabolism MH - PPAR alpha/*biosynthesis/genetics MH - Phosphorylation MH - RNA Interference MH - RNA, Messenger/biosynthesis MH - RNA, Small Interfering MH - Signal Transduction/genetics MH - Transcription Factor RelA/genetics MH - Tumor Necrosis Factor-alpha/*metabolism EDAT- 2012/11/13 06:00 MHDA- 2013/06/20 06:00 CRDT- 2012/11/13 06:00 PHST- 2012/04/23 00:00 [received] PHST- 2012/09/27 00:00 [revised] PHST- 2012/10/10 00:00 [accepted] PHST- 2012/11/13 06:00 [entrez] PHST- 2012/11/13 06:00 [pubmed] PHST- 2013/06/20 06:00 [medline] AID - S1043-4666(12)00740-5 [pii] AID - 10.1016/j.cyto.2012.10.007 [doi] PST - ppublish SO - Cytokine. 2013 Jan;61(1):266-74. doi: 10.1016/j.cyto.2012.10.007. Epub 2012 Nov 8.